ASAnand Shinde

Anand Shinde

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anand Shinde has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Concise Route to Lenacapavir Sodium: First Demonstration of One-Pot Heck-Suzuki Coupling in Lenacapavir API Synthesis

    by Limei Jin, Daryl Guthrie, Anand Shinde, Ramesh Vediyappan, Aline De Souza, Rama Sayini, John Saathoff, Nagaraju Sakkani, Naeem Asad, Sam Hochstetler, et al.

    This article presents a new three-step process for lenacapavir sodium, a first-in-class HIV capsid inhibitor developed by Gilead Sciences. Lenacapavir has received FDA approval for both treatment of multi-drug resistant HIV (Sunlenca®, 2022) and PrEP (Yeztugo®, 2025). Previous medicinal chemistry synthetic routes relied on separate Pd-catalyzed cou-plings and involved atropisomeric intermediates, resulting in low efficiency. Gilead’s 2024 four-step process improved scalability but retained discrete Pd-catalyzed steps and early-stage incorporation of the costly chiral pyrazole carboxylic acid (Frag C). Our streamlined approach begins with a chiral bromopyridine (Frag A) and features a telescoped Heck-Suzuki coupling and late-stage amidation with Frag C. This marks the first reported one-pot Heck-Suzuki sequence in the synthesis of lenacapavir, minimizing atropisomer handling and simplifying Pd sequestration. The process yields lenaca-pavir API in 50–55% overall yield, with >99.9 wt% purity, and Pd content below 4.2 ppm.